SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or...
LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
Jallal, an internationally recognized biopharma leader, oversaw historic approval of the world’s first TCR therapySeattle, WA, March 23, 2023 (GLOBE...
‘Mindful by Lucy’ Mushroom Microdose SupplementsVANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or...
Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition...
DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic...
Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP...
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Launches New E-commerce Initiatives with BoxoutMIAMI, March 23, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for...
Company to host a “Tech Talk” featuring client CalvertHealth on March 27thPLEASANTON, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Healthcare...
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA Oak Ridge, TN, March 23, 2023 (GLOBE...
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that NXC-201 treatment...
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing...
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with...
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and...
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
Company to host an investor conference call and webcast at 4:30 pm ETNEW YORK, March 23, 2023 (GLOBE NEWSWIRE) --...